2(1H)-Quinazolinone, 4-(2-cyclopropylethynyl)-5,6-difluoro-3,4-dihydro-4-(trifluoromethyl)-, (4S)-

Request For Quotation
2(1H)-Quinazolinone, 4-(2-cyclopropylethynyl)-5,6-difluoro-3,4-dihydro-4-(trifluoromethyl)-, (4S)- Suppliers list
Company Name: TargetMol Chemicals Inc.  
Tel: +1-781-999-5354; +1-00000000000
Email: marketing@targetmol.com
Company Name: Suzhou Meishi Biotechnology Co., Ltd.  
Tel: 1173954148q
Email: meishipharma@126.com
Company Name: TargetMol Chemicals Inc.  
Tel: 15002134094
Email: marketing@targetmol.cn
Company Name: TargetMol Chemicals Inc.  
Tel: 13564774135
Email: marketing@targetmol.com

2(1H)-Quinazolinone, 4-(2-cyclopropylethynyl)-5,6-difluoro-3,4-dihydro-4-(trifluoromethyl)-, (4S)- manufacturers

  • DPC-963
  • DPC-963 pictures
  • $1980.00
  • 2026-07-27
  • CAS:214287-90-8
  • Purity:
  • Supply Ability: 10g
2(1H)-Quinazolinone, 4-(2-cyclopropylethynyl)-5,6-difluoro-3,4-dihydro-4-(trifluoromethyl)-, (4S)- Basic information
Product Name:2(1H)-Quinazolinone, 4-(2-cyclopropylethynyl)-5,6-difluoro-3,4-dihydro-4-(trifluoromethyl)-, (4S)-
Synonyms:2(1H)-Quinazolinone, 4-(2-cyclopropylethynyl)-5,6-difluoro-3,4-dihydro-4-(trifluoromethyl)-, (4S)-;DMP 963;DMP963;DMP-963
CAS:214287-90-8
MF:C14H9F5N2O
MW:316.23
EINECS:
Product Categories:
Mol File:214287-90-8.mol
2(1H)-Quinazolinone, 4-(2-cyclopropylethynyl)-5,6-difluoro-3,4-dihydro-4-(trifluoromethyl)-, (4S)- Structure
2(1H)-Quinazolinone, 4-(2-cyclopropylethynyl)-5,6-difluoro-3,4-dihydro-4-(trifluoromethyl)-, (4S)- Chemical Properties
Melting point 187 °C
Boiling point 340.3±42.0 °C(Predicted)
density 1.54±0.1 g/cm3(Predicted)
pka7.84±0.40(Predicted)
Safety Information
MSDS Information
2(1H)-Quinazolinone, 4-(2-cyclopropylethynyl)-5,6-difluoro-3,4-dihydro-4-(trifluoromethyl)-, (4S)- Usage And Synthesis
UsesDPC-963 is an oral active non-nucleoside reverse transcriptase inhibitor with the IC50 of 18 nM. DPC-963 can be used for study of HIV[1][2].
References[1] Corbett JW, et al. Expanded-spectrum nonnucleoside reverse transcriptase inhibitors inhibit clinically relevant mutant variants of human immunodeficiency virus type 1. Antimicrob Agents Chemother. 1999;43(12):2893-2897. DOI:10.1128/AAC.43.12.2893
[2] Corbett JW, et al. Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors. J Med Chem. 2000;43(10):2019-2030. DOI:10.1021/jm990580e
2(1H)-Quinazolinone, 4-(2-cyclopropylethynyl)-5,6-difluoro-3,4-dihydro-4-(trifluoromethyl)-, (4S)- Preparation Products And Raw materials
Tag:2(1H)-Quinazolinone, 4-(2-cyclopropylethynyl)-5,6-difluoro-3,4-dihydro-4-(trifluoromethyl)-, (4S)-(214287-90-8) Related Product Information
2(1H)-Quinazolinone, 4-(2-cyclopropylethynyl)-5,6-difluoro-3,4-dihydro-4-(trifluoromethyl)- 2(1H)-Quinazolinone, 4-[(1E)-2-cyclopropylethenyl]-5,6-difluoro-3,4-dihydro-4-(trifluoromethyl)-, (4S)- 2(1H)-Quinazolinone, 4-(2-cyclopropylethynyl)-5,6-difluoro-3,4-dihydro-4-(trifluoromethyl)-, (4S)- 2(1H)-Quinazolinone, 6-chloro-4-(2-cyclopropylethynyl)-3,4-dihydro-4-(trifluoromethyl)- (4S)-6-Chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-3,4-dihydroquinazolin-2(1H)-one Doxorubicin hydrochloride